OneSkin announced on Wednesday the closing of its Series A funding round, bringing its total funding to $20 million. 

The funding is expected to allow OneSkin to enter a new era of research, development, and growth, furthering its mission to redefine skin aging through cutting-edge scientific advancements.

In particular, OneSkin will expand its research initiatives, develop innovative formulas, and broaden its reach in the anti-aging skincare industry. Moreover, the brand will focus on growth by increasing its human capital and exploring new sales channels.

The oversubscribed round was led by Selva Ventures, with additional backing from Plus Capital, Unilever Ventures, Able Partners, and continued support from previous investors SOSV and Meta Planet. 

“At OneSkin, we are excited to announce this new round of funding, which will further drive our mission to transform how we think about our skin, not only by optimizing our aesthetics using cutting-edge science, but also focusing on its functional role as our largest organ and the impact in our overall health and longevity,” said Carolina Oliveira, co-founder and CEO. 

Dr. Alessandra Zonari, co-dounder and CSO, added: “This investment will allow us to deepen our commitment to be the best in class in delivering efficacious peptides to modulate aging at the cellular level, ensuring that our science-backed solutions deliver measurable results in promoting healthier skin. We are dedicated to advancing the future of skin health with the most advanced longevity research and innovation.”

Founded in 2016 by a team of four Brazilian PhD scientists, OneSkin has been a first-to-market category leader in science-led topical skin longevity treatments. Its patented peptide and core ingredient, OS-01, is clinically proven to reverse skin’s biological age. 

Recognized by Fast Company as one of 2024’s Most Innovative Companies, OneSkin has attracted a high-profile clientele that includes figures like Alana Hadid, Georgia May Jagger, and Katy Perry.